EA201790650A1 - Лекарственная форма и способы применения абиратерона ацетата - Google Patents

Лекарственная форма и способы применения абиратерона ацетата

Info

Publication number
EA201790650A1
EA201790650A1 EA201790650A EA201790650A EA201790650A1 EA 201790650 A1 EA201790650 A1 EA 201790650A1 EA 201790650 A EA201790650 A EA 201790650A EA 201790650 A EA201790650 A EA 201790650A EA 201790650 A1 EA201790650 A1 EA 201790650A1
Authority
EA
Eurasian Patent Office
Prior art keywords
methods
application
abiraterone acetate
dosage form
compositions
Prior art date
Application number
EA201790650A
Other languages
English (en)
Russian (ru)
Inventor
Маура Мерфи
Пол Немет
Х. Уилльям Бош
Мэттью Каллахан
Сатя Бхамидипати
Джейсон Коулмен
Кристофер Хилл
Марк Норрет
Original Assignee
Айсьютика Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55533897&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201790650(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US14/707,922 external-priority patent/US20150246060A1/en
Application filed by Айсьютика Инк. filed Critical Айсьютика Инк.
Publication of EA201790650A1 publication Critical patent/EA201790650A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Epoxy Compounds (AREA)
EA201790650A 2014-09-18 2015-09-18 Лекарственная форма и способы применения абиратерона ацетата EA201790650A1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462052294P 2014-09-18 2014-09-18
US14/707,922 US20150246060A1 (en) 2013-03-15 2015-05-08 Abiraterone Acetate Formulation and Methods of Use
PCT/US2015/050889 WO2016044701A1 (en) 2014-09-18 2015-09-18 Abiraterone acetate formulation and methods of use

Publications (1)

Publication Number Publication Date
EA201790650A1 true EA201790650A1 (ru) 2017-07-31

Family

ID=55533897

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201790650A EA201790650A1 (ru) 2014-09-18 2015-09-18 Лекарственная форма и способы применения абиратерона ацетата

Country Status (17)

Country Link
EP (1) EP3193857A4 (enExample)
JP (1) JP2017528457A (enExample)
KR (2) KR102491439B1 (enExample)
CN (1) CN106687112A (enExample)
AP (1) AP2017009804A0 (enExample)
AU (1) AU2015317466A1 (enExample)
BR (1) BR112017003219A2 (enExample)
CA (1) CA2958316A1 (enExample)
CO (1) CO2017002472A2 (enExample)
EA (1) EA201790650A1 (enExample)
IL (1) IL250270B (enExample)
MD (1) MD20170048A2 (enExample)
MX (1) MX2017003525A (enExample)
PH (1) PH12017500239A1 (enExample)
SG (1) SG11201701139YA (enExample)
TN (2) TN2018000318A1 (enExample)
WO (1) WO2016044701A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3824908A1 (en) 2015-04-10 2021-05-26 Capsugel Belgium NV Abiraterone acetate lipid formulations
CA3061267A1 (en) * 2017-04-07 2018-10-11 Maa Laboratories, Inc. Methods of improving the solubility and bioavailability of therapeutic agents
JP2022523704A (ja) * 2019-01-25 2022-04-26 シェンチェン・ファーマシン・カンパニー・リミテッド 医薬組成物
CN114026106B (zh) 2019-03-06 2025-01-21 普洛拉治疗公司 阿比特龙前药
CN110742870B (zh) * 2019-12-04 2021-04-20 武汉大学 醋酸阿比特龙制剂及其制备方法
CN111110646A (zh) * 2020-02-19 2020-05-08 纳兰迦(上海)生物医药科技有限公司 一种低规格醋酸阿比特龙口服制剂的处方及制备方法
CN113384542B (zh) * 2020-03-14 2024-03-29 鲁南制药集团股份有限公司 一种甾体cyp17抑制剂固体分散体的片剂及其制备方法
US20230158047A1 (en) * 2020-04-16 2023-05-25 Tavanta Therapeutics Hungary Incorporated Methods and compositions for treating prostate cancer
JP2023524794A (ja) * 2020-05-08 2023-06-13 ヤンセン ファーマシューティカ エヌ．ベー． アビラテロン酢酸エステルとニラパリブの組み合わせによる前立腺癌の処置
EP3944860A1 (en) 2020-07-30 2022-02-02 Galenicum Health S.L.U. Abiraterone for use in a method of treating cancer
CN117120034A (zh) 2021-02-15 2023-11-24 普洛佩拉治疗公司 阿比特龙前药
KR20240145412A (ko) 2023-03-27 2024-10-07 한미약품 주식회사 아비라테론 아세테이트 및 프레드니솔론을 포함하는 약제학적 제제 및 이의 제조방법

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20160148041A (ko) * 2009-04-24 2016-12-23 아이슈티카 피티와이 리미티드 캅셀화된 나노입자의 상업적 규모의 생산
GB201207886D0 (en) * 2012-05-04 2012-06-20 Jagotec Ag Improvements in or relating to organic compounds
WO2014009436A1 (en) * 2012-07-11 2014-01-16 Sandoz Ag Nanosuspension of abiraterone acetate
WO2014009437A1 (en) * 2012-07-11 2014-01-16 Sandoz Ag Oxidation stability of abiraterone acetate
WO2014009434A1 (en) * 2012-07-11 2014-01-16 Sandoz Ag Self-microemulsifying drug delivery system of abiraterone or abiraterone acetate
CN102743393A (zh) 2012-07-27 2012-10-24 海南盛科生命科学研究院 一种含有醋酸阿比特龙的药物组合物及制备工艺
TWI686212B (zh) * 2013-03-15 2020-03-01 阿聯商太陽法瑪全球有限公司 醋酸阿比特龍配方

Also Published As

Publication number Publication date
SG11201701139YA (en) 2017-03-30
CO2017002472A2 (es) 2017-07-11
KR20230014878A (ko) 2023-01-30
TN2018000318A1 (en) 2020-01-16
JP2017528457A (ja) 2017-09-28
MD20170048A2 (ro) 2017-08-31
TN2017000098A1 (en) 2018-10-19
AU2015317466A1 (en) 2017-02-23
AP2017009804A0 (en) 2017-03-31
IL250270B (en) 2021-02-28
PH12017500239A1 (en) 2017-07-03
EP3193857A1 (en) 2017-07-26
WO2016044701A1 (en) 2016-03-24
BR112017003219A2 (pt) 2017-11-28
KR102491439B1 (ko) 2023-01-25
EP3193857A4 (en) 2018-04-11
CN106687112A (zh) 2017-05-17
MX2017003525A (es) 2017-06-21
KR102617537B1 (ko) 2023-12-22
IL250270A0 (en) 2017-03-30
KR20170070025A (ko) 2017-06-21
CA2958316A1 (en) 2016-03-24

Similar Documents

Publication Publication Date Title
IL272367A (en) Anti-cd39 antibodies, compositions comprising anti-cd39 antibodies and methods of using anti-cd39 antibodies
EA201891083A1 (ru) Составы антител к cd38 для подкожного введения и их применение
DOP2017000078A (es) Indazoles sustituidos con bencilo como inhibidores de bub1.
MX2023008686A (es) Polinucleotidos moduladores.
LT3674298T (lt) Pakeistieji indazolai, jų gavimo būdas, juos turinčios farmacinės kompozicijos ir jų panaudojimas vaistų gamybai
EA201891087A1 (ru) Ингибиторы ret
EA201691945A1 (ru) Антитела к гемагглютинину вируса гриппа типа b и способы их применения
EA201591728A1 (ru) Гетероциклические соединения и способы их применения
EA201691582A1 (ru) Новые фармацевтические препараты
DK3236943T3 (da) Sammensætninger til ileo-jejunal lægemiddeladministration
BR112016015706A2 (pt) composto, uso do mesmo e composição farmacêutica
PH12017500239A1 (en) Abiraterone acetate formulation and methods of use
DK3153169T3 (da) Fremgangsmåde til behandling af tumor, farmaceutisk sammensætning og medicinæskesæt
EA202091397A1 (ru) Бензохинолоновые ингибиторы vmat2
LT3116491T (lt) Terapiškai aktyvių junginių farmacinės kompozicijos
MX373309B (es) Composiciones antibióticas de ceftolozano.
DK3672631T3 (da) Farmaceutiske sammensætninger indeholdende anti-beta-amyloid-antistoffer
EA201791454A1 (ru) Лекарственные формы для трансдермального введения
TR201821116A2 (tr) POSAKONAZOL İÇEREN FARMASÖTİK BİLEŞİMLER ve ÜRETİM YÖNTEMİ
EP3429589A4 (en) PHARMACEUTICAL COMPOSITION OF NILOTINIB
ZA201703467B (en) Methods of treating ocular conditions
CL2017000587A1 (es) Derivados de tetrahidroquinolina como inhibidores de bromodominio
PH12016501686A1 (en) Pharmaceutical compositions of sitagliptin
EA201890364A1 (ru) СОЕДИНЕНИЯ, ПРИГОДНЫЕ ДЛЯ ИНГИБИРОВАНИЯ ROR-ГАММА-t
EA201792262A1 (ru) Пироглутамат вортиоксетина